A three-judge panel at the 5th U.S. Circuit Court of Appeals in New Orleans is set to hear arguments in a case that could impact how the abortion drug mifepristone is distributed across the country. Louisiana, which has nearly banned abortions, is challenging the U.S. Food and Drug Administration (FDA) over its rules that allow mifepristone to be prescribed via telehealth and mailed directly to patients. Louisiana claims these rules conflict with its near-total abortion ban and violate state authority, arguing the FDA hasn’t provided enough safety data to justify allowing mail delivery of the drug. According to the Guttmacher Institute, nearly 91,000 abortions in the U.S. last year were conducted using telehealth prescriptions for mifepristone sent by mail, with over 9,300 of those in Louisiana. The Trump administration is caught in a political dilemma over the case. While it has not supported the Biden administration's stance on the issue, it also has not yet officially joined the lawsuit, which has frustrated some conservative lawmakers. Louisiana’s Attorney General, Todd Blanche, has vowed to block mifepristone from being mailed, citing concerns that young women might receive the drug without proper guidance. In a private call with religious leaders, Blanche explained that the restrictions aim to prevent pills from being sent to states where abortion is illegal. The Justice Department has asked courts to delay lawsuits against mifepristone until the FDA finishes a safety review, which is expected to take six months. However, a Louisiana federal judge has set a deadline for an update on October 7, which could result in some review findings being available weeks before the midterm elections. Anti-abortion groups hope the review will lead to restrictions, but they want the FDA to act faster. The administration insists the process requires time, but conservative states are pushing ahead regardless. The Louisiana case is one of several federal lawsuits that could affect access to mifepristone via telehealth across the country, with others pending in Missouri and Texas. The Texas case was paused by a federal judge in late August, while the Missouri case is still being prepared. In Louisiana, a federal judge initially found the state had a strong legal argument but paused the case to wait for the FDA’s review. Louisiana appealed, and in May the 5th Circuit ruled in the state’s favor, temporarily blocking telehealth prescriptions for mifepristone nationwide. The Supreme Court then paused that ruling and sent the case back after the drug’s two manufacturers appealed. The Justice Department has not taken a formal position, though other Republican-led states and lawmakers have. Mifepristone has been used by more than 7.5 million people in the U.S. since the FDA approved it over 20 years ago, primarily for medication abortions and miscarriage care. It is considered safe and effective when used with another drug called misoprostol, offering an alternative to surgical abortions. The FDA has consistently found mifepristone to be safe, and it has relaxed access to the drug through several regulatory changes in 2016 and 2023. Anti-abortion groups have been working to limit its availability since then. The first major legal challenge to mifepristone came in 2022, when anti-abortion doctors and medical organizations sued to revoke the drug’s approval. While lower courts agreed, the Supreme Court in 2024 ruled unanimously that these groups did not have the legal right to sue. The 5th Circuit, which is considered one of the most conservative appeals courts, has a panel that includes two judges appointed by Democratic presidents. Legal experts suggest the case is likely to reach the Supreme Court, and the combination of the FDA’s ongoing review, other pending lawsuits, and the high court’s involvement has made the situation resemble political theater.